31 results about "Herpesviridae" patented technology

To provide a medicine, particularly a pharmaceutical composition useful for preventing or treating a variety of diseases caused by infection of a virus of the Herpesviridae family. [MEANS FOR SOLVING PROBLEMS] The present invention relates to an anti-herpesvirus agent characterized by combining a helicase-primase inhibitor with a polymerase inhibitor. By combining the helicase-primase inhibitor with the polymerase inhibitor having different action mechanisms, the anti-herpesvirus agent of the present invention achieves a dramatically superior anti-herpesvirus action compared with conventional administration of a polymerase inhibitor alone. Therefore, it is particularly effective in a case in which a sufficient therapeutic effect cannot be achieved only with a polymerase inhibitor. Further, the doses of both agents can be kept low, therefore it is also possible to perform treatment by lowering the effect of an adverse reaction to be concerned.

Viral infections of the eye, and particularly viral infections in the Herpesviridae and Adenoviridae families, can be treated by administration of a pharmaceutical made up of an enzymatically active ribonuclease and a vehicle. Advantageously, the enzymatically active ribonuclease is ranpirnase, the '805 variant, rAmphinase 2, and Amphinase 2, and the vehicle is an aqueous solution.

The present invention provides a medicament, in particular, a novel compound for preventing or treating various infections caused by herpesviridae viruses, especially infections caused by various herpes viruses, such as those caused by varicella zoster virus. Varicella (chickenpox), varicella zoster caused by multiple infections of latent varicella-zoster virus, cold sores and herpes encephalitis caused by HSV-1 infection, and genital herpes caused by HSV-2 infection. The present invention provides N-{2-[(4-substituted phenyl)amino]-2-oxoethyl}tetrahydro-2H-thiopyran-4-carbamoyl derivatives and salts thereof, wherein, phenyl The 4-position is substituted by a specific 5- or 6-membered heteroaryl group, it has effective antiviral activity, and it can be administered orally at a low dose to treat the above-mentioned diseases.

The present invention provides isolated nucleic acid molecules encoding a Herpesviridae thymidine kinase enzyme comprising one or more mutations, at least one of the mutations encoding an amino acid substitution located toward the N-terminus from a DRH nucleoside binding site which increases a biological activity of the thymidine kinase, as compared to unmutated thymidine kinase. Such mutations include amino acid substitutions within a Q substrate binding domain which increases a biological activity of the thymidine kinase, as compared to unmutated thymidine kinase. Within a further aspect, fusion proteins are provided which have both guanylate kinase and thymidine kinase biological properties. Also provided are vectors suitable for expressing such DNA molecules, as well as methods for utilizing such vectors.

The invention discloses a recombinant porcine pseudorabies virus (Herpesviridae) strain used for expression of porcine circovirus type II ORF2 gene. Preservation number of the recombinant porcine pseudorabies virus strain is CCTCC No.V201315. According to the preparation method, PCV2ORF2 gene is inserted into common carrier PG so as to construct transferring plasmid PGO; monolayer ST cells are inoculated with PRVTK<-> / gG<-> / gE<-> virus by 2h of adsorption; ST cells are transfected with plasmid PGO, wherein fusion degree of the monolayer ST cells is 80 to 90%; the recombinant porcine pseudorabies virus PGO strain is obtained by plaque purification, and is used for immunization of mouse. It is shown by results that commercial PCV2 inactivated vaccine and a group immunized by the recombinant porcine pseudorabies virus PGO strain are both capable of inducing specific humoral immune response of mouse, antibody titers of both the commercial PCV2 inactivated vaccine and the group are obviously higher than that of a group immunized by DMEM medium, and difference is significant (p<0.05). It is shown by the results of mouse lymphocyte proliferation test that specific ceullar immune response caused by the group immunized by the recombinant porcine pseudorabies virus PGO strain is more obvious than that caused by the commercial PCV2 inactivated vaccine and the group immunized by DMEM medium, and difference is obvious (p<0.05). In addition, the group immunized by the recombinant porcine pseudorabies virus PGO strain is capable of resisting severe attack by PCV2. Therefore application of the recombinant porcine pseudorabies virus strain in development of a novel PCV2 vaccine is possible.

The invention relates to a medical microorganism of the herpesviridae family, in particular to a live attenuated varicella vaccine. The present invention is prepared by the following method: (1) continuously passaging MRC-5 cells; (2) inoculating into cells and continuously infecting; (3) adding culture medium; (4) washing the cell surface; (5) washing out the infection The cells are separated by centrifugation, and the vaccine solution containing a stabilizer is added for freezing; (6) the virus stock solution is obtained by ultrasonic crushing and centrifugation; (7) combined and diluted, and immediately subpackaged and freeze-dried to obtain a live attenuated varicella vaccine. The stabilizer is NaCl, KCl, KH2PO4, Na2HPO4 12H2O, sucrose, sodium glutamate, kanamycin, erythromycin and deionized water in a weight ratio of 3: 0.1: 0.2: 3.3: 50: 0.4: 0.1: 0.03:1000 dissolved in water prepared. The invention has the advantages of good safety and immunogenicity.